Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Arterra Bioscience SpA ( (IT:ARBS) ) has issued an announcement.
Arterra Bioscience S.p.A. has completed the sale of its entire shareholding in Longevity Bioscience S.r.l. to Exosomics S.p.A. as part of a corporate reorganization. This transaction aligns with Arterra’s strategic focus on developing naturally derived extracellular vesicles for various industrial sectors, including cosmetics and medical devices. The company remains dedicated to investing in innovative biotechnological solutions, maintaining its mission and growth strategy.
More about Arterra Bioscience SpA
Arterra Bioscience S.p.A. is an Italian green biotech company specializing in research and development in biotechnology. Listed on the Euronext Growth Milan market since 2019, Arterra focuses on developing products and processes using living organisms, with applications in cosmetics, agriculture, and nutraceuticals. The company is based in Naples and was founded in 2004 by Gabriella Colucci, leveraging her extensive research experience. Arterra is committed to bio-sustainable products and has established collaborations with various companies and research institutes worldwide.
Average Trading Volume: 14,721
Technical Sentiment Signal: Buy
Current Market Cap: €15.98M
For detailed information about ARBS stock, go to TipRanks’ Stock Analysis page.